Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT05310526 Completed - Obesity Clinical Trials

BALANCE Diet Implementation in Primary Health Care: a Cluster Randomized Type II Hybrid Implementation Study

Implementa-MAC
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

This is an implementation type II hybrid study with randomisation in cluster, whose objective is to compare two strategies of implementation of the Brazilian cardioprotective diet guidelines in primary health care in two Brazilian cities. All health professionals from the health units (clusters) randomized to the intervention group will receive training on the subject. The health professionals from the health units randomized to the control group will follow the usual activities, receiving only the printed guidelines, as usually done. After 6 months, the prescription rate of the Brazilian cardioprotective diet will be evaluated, as well as the quality of the diet of patients in both groups.

NCT ID: NCT05309057 Active, not recruiting - Obesity Clinical Trials

Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk

Start date: November 1, 2020
Phase:
Study type: Observational

Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. There is emerging evidence that intermittent fasting or energy restriction might be more beneficial than continuous energy restriction for some risk factors. The effect of intermittent fasting on risk factors associated with obesity, diabetes, and cardiovascular disease, however, is not clear. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, tthe Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis of randomized controlled trials of the effect of different intermittent fasting strategies on established cardiometabolic risk factors. The findings generated by this proposed knowledge synthesis will shape guide current guidelines and improve health outcomes by educating healthcare providers and patients, and by guiding future research design.

NCT ID: NCT05297383 Not yet recruiting - Obesity Clinical Trials

Pilot: Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA)

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The goal of this pilot study is to understand the combined effects of fish oil and exercise in obesity-associated inflammation acutely. We hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and reduce inflammation and metabolic risk.

NCT ID: NCT05295719 Not yet recruiting - Obesity Clinical Trials

Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health

HIIT&PUFA
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The goal of this project is to understand the combined effects of fish oil and exercise in obesity-associated inflammation. The investigators hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and improve energy utilization and reduce inflammation and metabolic risk.

NCT ID: NCT05285085 Completed - Stroke Clinical Trials

Real World Evidence Study of Statin Use in Brazil

RWE-Statins
Start date: November 19, 2021
Phase:
Study type: Observational

A cross-sectional real-world data study designed to assess the use of statins in individuals assisted within the primary care system in Brazil.

NCT ID: NCT05266586 Completed - Clinical trials for Hypercholesterolemia

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

ROSE2
Start date: March 9, 2022
Phase: Phase 2
Study type: Interventional

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

NCT ID: NCT05259020 Recruiting - Hypertension Clinical Trials

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

Start date: February 22, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.

NCT ID: NCT05256654 Active, not recruiting - Dyslipidemias Clinical Trials

A Study of LY3561774 in Participants With Mixed Dyslipidemia

PROLONG-ANG3
Start date: July 20, 2022
Phase: Phase 2
Study type: Interventional

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.

NCT ID: NCT05245084 Completed - Clinical trials for Hypertension and Dyslipidemia

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

Start date: March 15, 2022
Phase: Phase 1
Study type: Interventional

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(3)

NCT ID: NCT05238012 Completed - Clinical trials for Metabolism Disorder, Glucose

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

XTREME
Start date: August 2, 2022
Phase: Phase 4
Study type: Interventional

This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes